Osteoporosis

>

Latest News

Prof. Dr. Med Peyman Hadji, Frankfurt Centre for Bone Health and Endocrinology, and Philipps University of Marburg, Germany
Teriparatide Biosimilar Demonstrates Therapeutic Equivalence in Postmenopausal Women With Osteoporosis

August 15th 2024

Both treatment arms experienced significant improvements in measured parameters from baseline, although these were not all statistically significant.

Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months
Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months

July 17th 2024

Patients with RA Have Higher Risk of Fractures
Patients with RA Have Higher Risk of Fractures

July 16th 2024

Proposed Denosumab Biosimilar AVT03 Demonstrates Positive Topline Data
Proposed Denosumab Biosimilar AVT03 Demonstrates Positive Topline Data

July 3rd 2024

FDA Approves Denosumab-bddz for Osteoporosis, Cancer-Related Skeletal Events
FDA Approves Denosumab-bddz for Osteoporosis, Cancer-Related Skeletal Events

March 5th 2024

© 2024 MJH Life Sciences

All rights reserved.